- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07558538
A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.
The trial is designed with three dose groups (5 mg, 10 mg, and 15 mg), which will be escalated sequentially from the lowest dose group to the highest dose group. Each dose group will enroll 8 subjects, randomized in a 6:2 ratio according to the order of enrollment, to receive either the corresponding dose of rhKGF-2 (6 subjects) or serve as a blank control (2 subjects). Each subject will receive a single dose, administered once via a disposable bronchoscopic catheter.
All subjects will receive the trial intervention on top of standard ARDS treatment (see Concomitant Medications for details). Following the completion of drug administration, subjects will enter a 28-day follow-up period. Outcome measures include adverse events (AE), vital signs, laboratory parameters, oxygenation index (PFR), chest imaging changes, etc., to evaluate the safety, tolerability, and efficacy of the treatment.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Première phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yi Wei
- Numéro de téléphone: +86 18872984075
- E-mail: yiwei4075@163.com
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200000
- Recrutement
- ShanghaiZhongshan
-
Contact:
- Yi Wei
- Numéro de téléphone: +86 18872984075
- E-mail: yiwei4075@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Aged ≥18 years and <80 years, male or female.
- Definite diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin Definition.
- Patients with PaO₂/FiO₂ < 200 mmHg and receiving invasive mechanical ventilation via endotracheal intubation.
- Diagnosis of ARDS confirmed no more than 72 hours prior to enrollment.
- No plan for parenthood within 1 year and agree to take effective contraceptive measures during the study period. Female participants of childbearing potential must have a negative serum pregnancy test.
The subject fully understands the purpose of the study, as well as the nature, methods, and potential reactions of the investigational drug. The subject voluntarily signs the informed consent form to participate in the study and agrees to comply with the requirements of the study protocol. If the subject is unable to provide consent or has limited capacity to consent, consent must be obtained from the subject's legal guardian.
-
Exclusion Criteria:
- Use of inhaled pulmonary vasodilators (e.g., nitric oxide or prostaglandins).
- Current receipt or planned receipt of extracorporeal membrane oxygenation (ECMO) during the study period.
- Expected survival < 3 months due to causes other than respiratory failure.
- Cerebrovascular or cardiovascular events within 3 months prior to study drug administration, including unstable angina, congestive heart failure, myocardial infarction within the past 12 months, hemodynamic instability, known left ventricular ejection fraction (LVEF) < 40%, or clinically significant arrhythmia or conduction abnormality.
- Inability to tolerate single-use bronchoscopic imaging catheter examination, including but not limited to the following: active massive hemoptysis; severe hypertension and arrhythmia; myocardial infarction or unstable angina within 4-6 weeks prior to screening; severe cardiac dysfunction; uncorrectable bleeding tendency (platelet count < 60 × 10⁹/L), such as severe coagulation disorders, uremia, or severe pulmonary hypertension; severe superior vena cava syndrome; suspected aortic aneurysm; multiple pulmonary bullae.
- History of severe allergic reaction, or known allergy or hypersensitivity to any component of the investigational product.
- Breastfeeding or pregnant women.
- Participation in any drug clinical trial within 3 months prior to enrollment.
- Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 5 mg rhKGF-2
|
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
|
|
Aucune intervention: Blank Control for 5 mg Cohort
|
|
|
Expérimental: 10 mg rhKGF-2
|
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
|
|
Aucune intervention: Blank Control for 10 mg Cohort
|
|
|
Expérimental: 15 mg rhKGF-2
|
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
|
|
Aucune intervention: Blank Control for 15 mg Cohort
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of adverse events (AE) and incidence of adverse drug reactions (ADR);
Délai: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
|
Incidence of serious adverse events (SAE)
Délai: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
|
Various laboratory test parameters:White blood cell (WBC) count
Délai: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Unit of measure: 3.5 - 9.5 × 10^9/L
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
Various Laboratory test parameters: Serum creatinine (Cr) level
Délai: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Unit of measure: 44 -115 μmol/L
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
Various laboratory test parameters: Total Bilirubin
Délai: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Unit of measure: 3.4-20.4
umol /L
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
Incidence of airway spasm (increased airway resistance) caused by local drug stimulation
Délai: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Improvement rate of oxygenation indexPaO₂/FiO₂ ratio (PFR)
Délai: at Day 3 and Day 7
|
at Day 3 and Day 7
|
|
|
PaO₂/FiO₂ ratio (PFR) and its change from baseline
Délai: at Day 3, Day 5, and Day 7
|
at Day 3, Day 5, and Day 7
|
|
|
Number of days from baseline to first PaO₂/FiO₂ ratio (PFR) > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
Délai: From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
|
From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
|
|
|
Change from baseline in the Murray Lung Injury Score(LIS).
Délai: at Day 7
|
Score (scale range: 0-4; higher scores indicate more severe lung injury)
|
at Day 7
|
|
Change from baseline in Radiographic Assessment of Lung Edema (RALE) score;
Délai: at Day 3, Day 7, Day 14, and Day 28
|
Score (scale range: 0-48; higher scores indicate a worse outcome);
|
at Day 3, Day 7, Day 14, and Day 28
|
|
Proportion of patients with improvement in ARDS severity grade
Délai: at Day 7 and Day 14
|
at Day 7 and Day 14
|
|
|
Proportion of patients with progression in ARDS severity grade
Délai: at Day 7 and Day 14
|
at Day 7 and Day 14
|
|
|
All-cause mortality
Délai: at Day 28
|
at Day 28
|
|
|
Systemic evaluation measures: Ventilator-free days at Day 28
Délai: at Day 28
|
Ventilator-free days at Day 28 (unit: days; higher scores indicate a better outcome).
|
at Day 28
|
|
Systemic evaluation measures: Non-ICU hospital stay days at Day 28
Délai: at Day 28.
|
Non-ICU hospital stay days at Day 28 (unit: days; higher scores indicate a better outcome as applicable).
|
at Day 28.
|
|
Systemic evaluation measures: Non-hospitalization days at Day 28
Délai: at Day 28
|
Non-hospitalization days at Day 28 (unit: days; higher scores indicate a better outcome).
|
at Day 28
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Yuanlin Song, Shanghai Zhongshan Hospital
- Chercheur principal: Jing Bi, Shanghai Zhongshan Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Maladies du système immunitaire
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies pulmonaires
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome non hodgkinien
- Lymphome
- Lésion pulmonaire
- Maladies hémiques et lymphatiques
- Lymphome folliculaire
- Lésion pulmonaire aiguë
- Phénomènes physiologiques circulatoires et respiratoires
- Mécanique respiratoire
- Respiration
- Phénomènes physiologiques respiratoires
- Inhalation
Autres numéros d'identification d'étude
- B2026-113R
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .